HKEx (388.HK): Trading Volume in May Points to Upside and New License Agreement with MSCI
HKEX (388 HK) just released its May market statistics. The May month ADT (Average Daily Turnover) has registered 14% month-to-month rebound to HKD...
532 Views
Kintor Pharma IPO: Valuation Insights
Kintor Pharmaceutical (9939 HK) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers and...
419 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
354 Views
ECM Weekly (26 Apr 2020) - Kingsoft Cloud, WeDoctor, Akesobio, Kotak Mahindra Bank
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Akeso...
530 Views
Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK)Ā is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
559 Views